Vedolizumab Dose Escalation: In for a Penny, in for a Pound?

Robin J Dart^{1

2}, Peter M Irving^{2

3}, Mark A Samaan⁴

Affiliations

¹ Department of Gastroenterology, Royal Free Hospital, London, UK.
² School of Immunology and Microbial Sciences, King's College London, London, UK.
³ Department of Gastroenterology, St Thomas' Hospital, Guy's & St Thomas', First Floor College House, North Wing, Westminster Bridge Road, London, SE1 7EH, UK.
⁴ Department of Gastroenterology, St Thomas' Hospital, Guy's & St Thomas', First Floor College House, North Wing, Westminster Bridge Road, London, SE1 7EH, UK. markasamaan@gmail.com.

Editorial

Robin J Dart et al. Dig Dis Sci. 2021 Jun.

. 2021 Jun;66(6):1772-1774.

doi: 10.1007/s10620-020-06565-z.

Robin J Dart^{1

2}, Peter M Irving^{2

3}, Mark A Samaan⁴

¹ Department of Gastroenterology, Royal Free Hospital, London, UK.
² School of Immunology and Microbial Sciences, King's College London, London, UK.
³ Department of Gastroenterology, St Thomas' Hospital, Guy's & St Thomas', First Floor College House, North Wing, Westminster Bridge Road, London, SE1 7EH, UK.
⁴ Department of Gastroenterology, St Thomas' Hospital, Guy's & St Thomas', First Floor College House, North Wing, Westminster Bridge Road, London, SE1 7EH, UK. markasamaan@gmail.com.

No abstract available

Comment on

Vedolizumab Dose Escalation Improves Therapeutic Response in a Subset of Patients with Ulcerative Colitis.
Perry C, Fischer K, Elmoursi A, Kern C, Currier A, Kudaravalli P, Akanbi O, Tripathi N, Yarra P, Su L, Flomenhoft D, Stromberg A, Barrett TA. Perry C, et al. Dig Dis Sci. 2021 Jun;66(6):2051-2058. doi: 10.1007/s10620-020-06486-x. Epub 2020 Jul 24. Dig Dis Sci. 2021. PMID: 32710192

1. Perry C, Fischer K, Elmoursi A, et al. Vedolizumab dose escalation improves therapeutic response in a subset of patients with ulcerative colitis. Dig Dis Sci. (Epub ahead of print). https://doi.org/10.1007/s10620-020-06486-x .
1. Peyrin-Biroulet L, Danese S, Argollo M, et al. Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn’s disease or ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:838–846. - DOI
1. Samaan MA, Birdi S, Morales MS, et al. Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response. Frontline Gastroenterol. 2020;11:188–193. - DOI
1. Ungar B, Kopylov U, Yavzori M, et al. Association of vedolizumab level, anti-drug antibodies, and alpha4beta7 occupancy with response in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16:697.e7–705.e7. - DOI
1. Rath T, Billmeier U, Ferrazzi F, et al. Effects of anti-integrin treatment with vedolizumab on immune pathways and cytokines in inflammatory bowel diseases. Front Immunol. 2018;9:1700. - DOI